ArticleTherapeutic innovation & regulatory science2026
Cardiovascular Toxicity of Monoclonal Antibodies Approved for Multiple Myeloma: Evidence Based on FAERS Database.
Article in Therapeutic innovation & regulatory science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundMonoclonal antibodies have emerged as effective therapeutic agents for multiple myeloma. However, monoclonal antibody-related cardiovascular toxicity is controversial and a comprehensive evaluation remains scarce.
methodsThis pharmacovigilance study utilized records for monoclonal antibodies approved for myeloma (including daratumumab, isatuximab, elotuzumab, belantamab mafodotin, teclistamab, elotuzumab, elranatamab and talquetamab) from the FAERS database (January 1, 2016, to December 31, 2024) via OpenVigil 2.1. Cardiovascular events were screened and broadly categorized based on the MedDRA v24.0 into eight standardized MedDRA queries (SMQs). Reporting odds ratio and information Component were utilized to measure disproportionality and potential risk signals.
resultsA total of 1160 cardiovascular toxicity events were identified from reports listing monoclonal antibodies as the primary suspect. Heart failure was the predominant cardiovascular toxicity associated with daratumumab, elotuzumab, and isatuximab, followed by embolic and thrombotic events. Additionally, daratumumab and isatuximab were linked to an elevated risk of hypertension, while only daratumumab led to increased risk of arrhythmia. Patients experiencing cardiac toxicity were predominantly male and aged ≥ 65 years. Monoclonal antibodies did not increase the risk of cardiomyopathy, pulmonary hypertension, ischemic heart disease, or torsade de pointes/QT prolongation.
conclusionThis study identified significant cardiovascular toxicity signals associated with monoclonal antibodies approved for myeloma, underscoring the importance of monitoring heart failure, embolic and thrombotic events, hypertension, and arrhythmia.
Indexed as
Identifiers
42289016What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.